PL2953973T3 - Środki wiążące muskarynowy receptor acetylocholiny i ich zastosowania - Google Patents

Środki wiążące muskarynowy receptor acetylocholiny i ich zastosowania

Info

Publication number
PL2953973T3
PL2953973T3 PL14703337T PL14703337T PL2953973T3 PL 2953973 T3 PL2953973 T3 PL 2953973T3 PL 14703337 T PL14703337 T PL 14703337T PL 14703337 T PL14703337 T PL 14703337T PL 2953973 T3 PL2953973 T3 PL 2953973T3
Authority
PL
Poland
Prior art keywords
receptor binding
binding agents
acetylcholine receptor
muscarinic acetylcholine
muscarinic
Prior art date
Application number
PL14703337T
Other languages
English (en)
Inventor
Jan Steyaert
Els Pardon
Brian Kobilka
Aaron RING
Andrew KRUSE
Aasish MANGLIK
Original Assignee
Vib Vzw
Vrije Universiteit Brussel
The Board Of Trustees Of The University Of The Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vib Vzw, Vrije Universiteit Brussel, The Board Of Trustees Of The University Of The Leland Stanford Junior University filed Critical Vib Vzw
Publication of PL2953973T3 publication Critical patent/PL2953973T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
PL14703337T 2013-02-05 2014-02-05 Środki wiążące muskarynowy receptor acetylocholiny i ich zastosowania PL2953973T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361761136P 2013-02-05 2013-02-05
US201361961058P 2013-10-03 2013-10-03
PCT/EP2014/052265 WO2014122183A1 (en) 2013-02-05 2014-02-05 Muscarinic acetylcholine receptor binding agents and uses thereof
EP14703337.7A EP2953973B1 (en) 2013-02-05 2014-02-05 Muscarinic acetylcholine receptor binding agents and uses thereof

Publications (1)

Publication Number Publication Date
PL2953973T3 true PL2953973T3 (pl) 2020-01-31

Family

ID=50070546

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14703337T PL2953973T3 (pl) 2013-02-05 2014-02-05 Środki wiążące muskarynowy receptor acetylocholiny i ich zastosowania

Country Status (10)

Country Link
US (3) US20150368339A1 (pl)
EP (2) EP3590578A1 (pl)
JP (2) JP2016512954A (pl)
AU (1) AU2014214054B2 (pl)
CA (1) CA2900147C (pl)
DK (1) DK2953973T3 (pl)
ES (1) ES2745772T3 (pl)
PL (1) PL2953973T3 (pl)
PT (1) PT2953973T (pl)
WO (1) WO2014122183A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201014715D0 (en) 2010-09-06 2010-10-20 Vib Vzw Nanobodies stabilizing functional conformational states of GPCRS
GB201601690D0 (en) 2016-01-29 2016-03-16 Heptares Therapeutics Ltd G proteins
JP2020504623A (ja) * 2017-01-05 2020-02-13 へリックス バイオファーマ コープ． 癌を治療するためのｖｅｇｆｒ−２ ｃａｒ免疫細胞
WO2018126316A1 (en) * 2017-01-05 2018-07-12 Helix Biopharma Corporation Vegfr-2 antibodies
EP3665201A4 (en) * 2017-08-09 2021-06-02 Orionis Biosciences, Inc. CD8 BINDERS
CA3076791A1 (en) 2017-10-31 2019-05-09 Vib Vzw Novel antigen-binding chimeric proteins and methods and uses thereof
CA3138642A1 (en) 2019-04-29 2020-11-05 Confo Therapeutics N.V. Screening methods and assays for use with transmembrane proteins, in particular with gpcrs
WO2021140205A1 (en) 2020-01-10 2021-07-15 Confo Therapeutics N.V. Methods for generating antibodies and antibody fragments and libraries comprising same

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU701578B2 (en) 1992-08-21 1999-02-04 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
FR2708622B1 (fr) 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
ES2294799T3 (es) 1996-06-27 2008-04-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Moleculas de anticuerpos que interactuan especificamente con el sitio activo o hendidura de una molecula diana.
WO1999037681A2 (en) 1998-01-26 1999-07-29 Unilever Plc Method for producing antibody fragments
BR9916765A (pt) 1999-01-05 2001-09-25 Unilever Nv Processo para produzir um material imunoadsorvente, uso de uma proteìna que é ligada por meio de uma ligação covalente a um fragmento de anticorpo, material imunadsorvente, uso de um material, e, kit de teste diagnóstico
DE60013767T3 (de) 1999-01-19 2009-07-09 Unilever N.V. Verfahren zur herstellung von antikörperfragmenten
CN1252264C (zh) 1999-04-22 2006-04-19 荷兰联合利华有限公司 利用单价抗原－结合蛋白抑制病毒感染
US6479280B1 (en) 1999-09-24 2002-11-12 Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
AU1859201A (en) 1999-11-29 2001-06-12 Unilever Plc Immobilisation of proteins
DE60042789D1 (de) 1999-11-29 2009-10-01 Bac Ip B V Immobilisierte antigenbindende moleküle aus einer domäne
ES2324280T3 (es) 2000-03-14 2009-08-04 Unilever N.V. Dominios variables de la cadena pesada de anticuerpos frente a lipasas dieteticas humanas y sus usos.
WO2001090190A2 (en) 2000-05-26 2001-11-29 National Research Council Of Canada Single-domain antigen-binding antibody fragments derived from llama antibodies
ATE513854T1 (de) 2000-12-13 2011-07-15 Bac Ip B V Proteinraster aus variablen domänen der schweren immunoglobulinkette von kamelen
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
EP1433793A4 (en) 2001-09-13 2006-01-25 Inst Antibodies Co Ltd METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
EP1456237A2 (en) 2001-12-21 2004-09-15 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Method for cloning of variable domain sequences
WO2003055527A2 (en) 2002-01-03 2003-07-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Immunoconjugates useful for treatment of tumours
CA2505316C (en) 2002-11-08 2014-08-05 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
WO2005044858A1 (en) 2003-11-07 2005-05-19 Ablynx N.V. Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
WO2004041867A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Camelidae antibodies against imminoglobulin e and use thereof for the treatment of allergic disorders
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
WO2004060965A2 (en) 2002-12-31 2004-07-22 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
EP1587838B1 (en) 2003-01-10 2015-04-15 Ablynx N.V. Therapeutic polypeptides, homologues thereof, fragments thereof and their use in modulating platelet-mediated aggregation
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
AU2005325801A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
WO2006122787A1 (en) 2005-05-18 2006-11-23 Ablynx Nv Serum albumin binding proteins
ES2852423T3 (es) 2005-05-20 2021-09-13 Ablynx Nv NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación
EP2057191A1 (en) 2006-08-18 2009-05-13 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
JP2010518839A (ja) 2007-02-21 2010-06-03 アブリンクス エン．ヴェー． 血管内皮増殖因子に指向性を有するアミノ酸配列、及び過度の及び／もしくは病的な血管形成又は血管新生を特徴とする症状及び疾患を治療するためにこれを含むポリペプチド
CN101796072B (zh) 2007-05-24 2014-09-24 埃博灵克斯股份有限公司 用于治疗骨疾病和病症的针对rank-l的氨基酸序列以及包括其的多肽
JP2012510806A (ja) 2008-12-08 2012-05-17 コンプリクス エン ヴェー 単鎖逆平行コイルドコイルタンパク質
EP3470425A3 (en) 2008-12-19 2019-07-17 Ablynx N.V. Immunoglobulins against cell-associatd antigens such as p2x7
WO2011083141A2 (en) 2010-01-08 2011-07-14 Ablynx Nv Method for generation of immunoglobulin sequences by using lipoprotein particles
GB201014715D0 (en) * 2010-09-06 2010-10-20 Vib Vzw Nanobodies stabilizing functional conformational states of GPCRS
DK2611826T3 (en) 2010-08-30 2017-01-09 Confometrx Inc A method and composition for the crystallization of a family-C-GPCR
US8765414B2 (en) 2011-03-15 2014-07-01 The Board Of Trustees Of The Leland Stanford Junior University GPCR fusion protein containing an N-terminal autonomously folding stable domain, and crystals of the same
US20120288913A1 (en) 2011-05-13 2012-11-15 The Scripps Research Institute Novel fusion partners for the purpose of crystallizing g-protein coupled receptors
WO2014118297A1 (en) * 2013-01-30 2014-08-07 Vib Vzw Novel chimeric polypeptides for screening and drug discovery purposes

Also Published As

Publication number Publication date
EP3590578A1 (en) 2020-01-08
AU2014214054A1 (en) 2015-08-20
WO2014122183A1 (en) 2014-08-14
DK2953973T3 (da) 2019-08-12
US20180222978A1 (en) 2018-08-09
EP2953973A1 (en) 2015-12-16
JP2019122378A (ja) 2019-07-25
AU2014214054B2 (en) 2018-10-04
CA2900147A1 (en) 2014-08-14
EP2953973B1 (en) 2019-07-10
PT2953973T (pt) 2019-10-25
JP2016512954A (ja) 2016-05-12
CA2900147C (en) 2023-09-05
US20210340249A1 (en) 2021-11-04
WO2014122183A9 (en) 2016-05-26
ES2745772T3 (es) 2020-03-03
JP6827485B2 (ja) 2021-02-10
US20150368339A1 (en) 2015-12-24

Similar Documents

Publication Publication Date Title
ZA201500872B (en) Rspo3 binding agents and uses thereof
ZA201602501B (en) Pyrrolobenzodiazepines and conjugates thereof
IL234719A0 (en) Anti-pmel17 antibodies and immunoconjugates
IL241532B (en) Pyrrolobenzodiazepines and their conjugates
ZA201506668B (en) Pyrrolobenzodiazepines and conjugates thereof
ZA201505753B (en) Pyrrolobenzodiazepines and conjugates thereof
SG11201405881TA (en) Anti-lgr5 antibodies and immunoconjugates
HUE043851T2 (hu) Anti-DLL3-antitest-PBD konjugátumok és alkalmazásuk
GB201317981D0 (en) Pyrrolobenzodiazepines and conjugates thereof
IL237176A0 (en) Anticholinergic preparation that protects the nervous system and methods
IL239643A0 (en) Converted morphines and their use
GB2513444B (en) Improved stopper device
IL254416B (en) Anti-asic1 antibodies and their uses
PL2953973T3 (pl) Środki wiążące muskarynowy receptor acetylocholiny i ich zastosowania
PL3016520T3 (pl) Kompozycje kremera i ich zastosowania
GB201604311D0 (en) Solids-free diverting agents and methods related thereto
GB201318151D0 (en) Composition and device
IL237400B (en) Rhizobacteria and its uses
GB201210989D0 (en) Composition and device
AU2013900167A0 (en) Alpha7 Nicotinic Acetylcholine Receptor Modulators and Uses Thereof-II
PL2641462T3 (pl) Urządzenie wiążące
GB201208372D0 (en) Antibodies and uses thereof